Vivek Agrawal CFA
Stock Analyst at Citi
(0.48)
# 4,188
Out of 4,581 analysts
21
Total ratings
50%
Success rate
-11.8%
Average return
Main Sectors:
Stocks Rated by Vivek Agrawal CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSE: CIPLA Cipla Limited | Maintained: Buy | n/a | $1,474.30 | - | 2 | Jul 24, 2026 | |
| NSE: SUNPHARMA Sun Pharmaceutical Industries Limited | Maintained: Buy | ₹2,180 | ₹1,990 | +9.55% | 2 | Sep 30, 2025 | |
| NSE: MAXHEALTH Max Healthcare Institute Limited | Maintained: Buy | ₹1,460 | ₹1,111 | +31.37% | 1 | Aug 11, 2025 | |
| NSE: AUROPHARMA Aurobindo Pharma Limited | Maintained: Sell | ₹1,100 → ₹1,010 | ₹1,591 | -36.51% | 3 | Aug 6, 2025 | |
| NSE: LAURUSLABS Laurus Labs Limited | Maintained: Sell | ₹500.00 → ₹590.00 | ₹1,781 | n/a | 2 | Jul 28, 2025 | |
| NSE: GLAND Gland Pharma Limited | Maintained: Sell | ₹1,680 | ₹2,544 | n/a | 1 | Jul 22, 2025 | |
| NSE: APOLLOHOSP Apollo Hospitals Enterprise Limited | Maintained: Buy | ₹8,260 | ₹8,935 | n/a | 1 | Jun 30, 2025 | |
| NSE: DRREDDY Dr. Reddy's Laboratories Limited | Maintained: Sell | ₹990.00 | ₹1,142 | n/a | 1 | Jun 27, 2025 | |
| NSE: DIVISLAB Divi's Laboratories Limited | Maintained: Buy | ₹7,050 → ₹7,750 | ₹7,785 | n/a | 2 | May 19, 2025 | |
| NSE: LALPATHLAB Dr. Lal PathLabs Limited | Maintained: Sell | ₹1,350 | ₹1,883 | n/a | 1 | Apr 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ₹700.00 | ₹664.55 | n/a | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | ₹2,260 | ₹2,447 | n/a | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ₹2,330 → ₹1,880 | ₹1,330 | n/a | 2 | Feb 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | ₹430.00 | ₹431.10 | n/a | 1 | Feb 3, 2025 |
Cipla Limited
Jul 24, 2026
Maintained: Buy
Price Target: n/a
Current: $1,474.30
Upside: -
Sun Pharmaceutical Industries Limited
Sep 30, 2025
Maintained: Buy
Price Target: ₹2,180
Current: ₹1,990
Upside: +9.55%
Max Healthcare Institute Limited
Aug 11, 2025
Maintained: Buy
Price Target: ₹1,460
Current: ₹1,111
Upside: +31.37%
Aurobindo Pharma Limited
Aug 6, 2025
Maintained: Sell
Price Target: ₹1,100 → ₹1,010
Current: ₹1,591
Upside: -36.51%
Laurus Labs Limited
Jul 28, 2025
Maintained: Sell
Price Target: ₹500.00 → ₹590.00
Current: ₹1,781
Upside: n/a
Gland Pharma Limited
Jul 22, 2025
Maintained: Sell
Price Target: ₹1,680
Current: ₹2,544
Upside: n/a
Apollo Hospitals Enterprise Limited
Jun 30, 2025
Maintained: Buy
Price Target: ₹8,260
Current: ₹8,935
Upside: n/a
Dr. Reddy's Laboratories Limited
Jun 27, 2025
Maintained: Sell
Price Target: ₹990.00
Current: ₹1,142
Upside: n/a
Divi's Laboratories Limited
May 19, 2025
Maintained: Buy
Price Target: ₹7,050 → ₹7,750
Current: ₹7,785
Upside: n/a
Dr. Lal PathLabs Limited
Apr 27, 2025
Maintained: Sell
Price Target: ₹1,350
Current: ₹1,883
Upside: n/a
Mar 12, 2025
Initiated Coverage: Buy
Price Target: ₹700.00
Current: ₹664.55
Upside: n/a
Mar 5, 2025
Upgraded: Buy
Price Target: ₹2,260
Current: ₹2,447
Upside: n/a
Feb 16, 2025
Maintained: Hold
Price Target: ₹2,330 → ₹1,880
Current: ₹1,330
Upside: n/a
Feb 3, 2025
Maintained: Buy
Price Target: ₹430.00
Current: ₹431.10
Upside: n/a